| 2/10/22 |
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022 |
| 2/10/22 |
Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2 |
| 2/8/22 |
Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global |
| 1/13/22 |
Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria |
| 1/13/22 |
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19 |
| 1/11/22 |
GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19 |
| 1/4/22 |
Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference |
